CD8A and COVID-19: First, single-cell technology has recently been applied to determine antibody responses and proliferative SARS-CoV-2-specific T cells’ capabilities in convalescent COVID-19 (Sekine et al. identified SARS-CoV-2-specific CD4+ and CD8+ T cells in convalescent individuals, exposed family members, and healthy blood donors).